CCR2 and neoplasm: To inhibit the recruitment of CCR2+ TAMs to the tumor site following iIRE, we incorporated a highly selective CCR2 inhibitor (PF-4136309), which is currently in phase 2 clinical trials for advanced PDAC (43), into our therapeutic strategy.